Abstracts
This study evaluates the difference in total hospital charges and length of stay (LOS) between peritoneal dialysis (PD) and hemodialysis (HD) patients. METHODS: Hospital inpatient data was analyzed from the Healthcare Cost and Utilization Project's 2006 National Inpatient Sample. Patients were identifi ed as HD or PD by a procedure code of 39.95 or 54.98, respectively, and a diagnosis code for end-stage renal disease (585.6). Exclusion criteria include having a procedure code for both PD and HD, a diagnosis code for acute renal failure (584.x), or under age 18. Differences in LOS and total charges were analyzed using univariate and multivariate analysis adjusted for age, gender, and comorbidities. Subgroup analyses were done by payer type. RESULTS: 530,409 HD and 22,031 PD discharges met inclusion and exclusion criteria. PD patients were younger, more female, and had less comorbidity. The mean total charge for a PD discharge was $35,846 compared to $41,336 for HD (p 0.0001). The mean LOS was 6.57 days for PD and 7.25 days for HD (p 0.0001). After adjusting for covariates, HD total charges were 13.9% higher than PD (p 0.0001) and LOS was 6.7% longer (p 0.0086). For Medicare patients, total charges were 10.0% higher in HD patients (p 0.0001) and LOS was not different between HD and PD. For patients with private insurance, mean total charges were 21.7% higher in HD patients (p 0.0001) and LOS was 9.2% greater (p 0.01). The charge difference, HD minus PD, between private and Medicare patients was signifi cantly higher in the former. CONCLUSIONS: Adjusted mean total charges and LOS were signifi cantly higher in patients receiving HD compared to PD. LOS was signifi cantly longer in privately insured HD patients but not in Medicare HD patients. The charge difference between HD and PD was signifi cantly higher in privately insured compared to Medicare patients.
PUK8 THE COST-EFFECTIVENESS OF PARICALCITOL VERSUS STANDARD TREATMENT FOR SECONDARY HYPERPARATHYROIDISM -MULTI-COUNTRY PERSPECTIVES
Nuijten M j 1 , Marx SE 2 , Sterz R 3 1 Ars Accessus Medica, Jisp, Netherlands, 2 Abbott Laboratories, Abbott Park, IL, USA, 3 Abbott GmbH & Co., Ludwigshafen, Germany OBJECTIVES: The objective of this study was to determine the cost effectiveness of paricalcitol versus standard treatment in patients with chronic kidney disease (CKD) in the health care setting in Italy, Portugal and Turkey in 2008. METHODS: A Markov process model was developed employing data sources from the published literature, paricalcitol clinical trials, offi cial country price/tariff lists and national population statistics. The comparator was the standard treatment for each country; Italy, Portugal, and Turkey. The primary perspective of the study was that of the society. The primary effi cacy outcome in the Paricalcitol (reduction SHPT, reduction proteinuria, complications and mortality) were extrapolated to effectiveness outcomes: number of life years gained (LYG) and number of quality-adjusted life-years (QALYs). Clinical and economic outcomes were discounted at 3.0%. RESULTS: The base case analysis is based on a 10-years time horizon and a comparison of paricalcitol in stage CKD 3, CKD 4 and CKD 5 versus standard treatment. The use of paricalcitol leads to an additional medical cost of €4335 to €6564; and an increase in life years gained of 0.48 to 0.67 years, and a gain in QALYs of 0.42 to 0.64. Consequently the use of paricalcitol results in an ICER of less than €11,000/QALY from the perspective of the society in all three countries. This value is well below the willingness to pay threshold.
CONCLUSIONS:
The results showed that the favorable clinical benefi t of paricalcitol results in positive short and long-term health economic benefi ts. This study suggests that the use of paricalcitol in patients with early chronic kidney disease may be cost-effective from a society perspective in Italy, Portugal and Turkey. tamsulosin (TAM) provides clinical benefi ts versus TOL or TAM monotherapy or placebo (PBO) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB). The present analysis estimated the costs and quality adjusted life years (QALYs) associated with these therapies from the perspective of the UK health care system. METHODS: TIMES cohorts receiving TOL, TAM, TOL TAM, or PBO were followed from therapy initiation to 12 weeks. A decision tree model was used to extrapolate the 12-week results to 1 year (including need for surgery owing to treatment failure at 12 weeks), and to track patients' outcomes (symptoms, utility, and costs). Because TIMES did not include costs and QALYs, data from the EpiLUTS epidemiologic survey (9416 males) were used to model a mathematical relationship between LUTS (daytime and nocturnal frequency, urgency episodes, urgency urinary incontinence episodes, and International Prostate Symptom Scores [IPSS]), quality of life, and utility. This was used to convert improvements in TIMES patients' LUTS into utility scores and QALYs. The model included drug and surgery procedure costs and hospital length of stay. RESULTS: Incremental QALYs of TOL TAM vs PBO, TAM and TOL were 0.033, 0.016 and 0.011, and corresponding incremental costs were 262, 253 and -30, respectively, resulting in cost-utility ratios for TOL TAM of 7,894/QALY gained compared with PBO, and 15,346/QALY gained compared with TAM. TOL TAM combination therapy was both more effective and cost-saving compared with TOL. Univariate sensitivity analyses showed that patient utility was most responsive to changes in IPSS score and number of urgency episodes. Changing the percentage of patients undergoing surgery did not substantially affect model outcomes. CONCLUSIONS: The TOL TAM combination therapy appears to be cost-effective compared with TOL or TAM monotherapy or PBO in male patients with LUTS.
PUK9 COST-EFFECTIVENESS ANALYSIS OF ALPHA-BLOCKER AND ANTI-MUSCARINIC COMBINATION TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS RELATED TO BENIGN PROSTATIC HYPERPLASIA AND OVERACTIVE BLADDER: APPLICATION TO THE UNITED KINGDOM

PUK10 LONG-TERM COST EFFECTIVENESS OF SIROLIMUS REGIMEN COMPARED WITH CALCINEURIN INHIBITOR REGIMENS FOR IMMUNOSUPPRESSION AFTER RENAL TRANSPLANTATION IN KOREA
Song HJ g J, Park SY, Kang SH, Bae JY, Lee EK Sook Myung Women's University, Seoul, South Korea OBJECTIVES: The calcineurin inhibitor (CNI) regimens, including tacrolimus or cyclosporine, have improved the overall success of renal transplantation through increased short-term patient and graft survival. However, this has not translated into
